The International Journal of Medical Science and Health Research
Vol. 49 No. 2 (2026): The International Journal of Medical Science and Health Research

EFFICACY OF ORAL NIFEDIPINE VERSUS LABETALOL IN THE EMERGENCY MANAGEMENT OF HYPERTENSIVE CRISIS IN PREGNANCY: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES

Made Krisna Wibawa Pramartha (Wangaya Regional General Hospital, Denpasar, Indonesia)



Article Info

Publish Date
03 Nov 2026

Abstract

Introduction: Hypertensive disorders complicate one in ten pregnancies and remain leading causes of maternal mortality worldwide. Severe hypertension (SBP ≥160 mmHg and/or DBP ≥110 mmHg) constitutes an obstetric emergency due to imminent risks of intracerebral hemorrhage, eclampsia, pulmonary edema, and placental abruption. Oral nifedipine and labetalol are the most widely used first-line agents, yet comparative evidence remains fragmented. This review aimed to determine whether oral nifedipine differs from labetalol in acute control of hypertensive crisis in pregnancy across fifteen pre-specified clinical outcomes. Methods: A systematic review was conducted per PRISMA 2020 guidelines. Eligible designs included RCTs, quasi-experimental trials, prospective/retrospective cohorts, case-control, and cross-sectional studies comparing nifedipine with labetalol in pregnant women with severe hypertension. Risk of bias was appraised with Cochrane RoB 2 and ROBINS-I; certainty with GRADE. A binormal ROC reconstruction was performed for time-to-target blood pressure, with AUC representing probability of earlier attainment. Results: Twenty-one primary studies (15 RCTs, 1 quasi-experimental, 2 prospective cohorts, 3 retrospective cohorts) comprising ≥9,889 pregnant women from ten countries were included. Oral nifedipine reached target BP significantly faster than labetalol: pooled MD -9.10 minutes (95% CI -13.69 to -4.51; τ²=11.55; I²=44.2%). Reconstructed pooled AUC was 0.668 (95% CI 0.609-0.727; I²=0.0%), significantly exceeding 0.500. Nifedipine required fewer doses, produced greater systolic/diastolic reduction, and increased urine output. Maternal/perinatal adverse events, caesarean delivery, fetal heart-rate abnormality, Apgar<7, and NICU admission did not differ significantly. One large observational cohort favored labetalol for composite maternal morbidity (aRR 1.33, 95% CI 1.07-1.64). Risk of bias was low in 5/15 RCTs, moderate-to-serious in all non-randomized studies. GRADE certainty was moderate for time-to-target and dose requirement, low/very low for patient-important outcomes. Discussion: Nifedipine's pharmacodynamic superiority in speed and dose economy is consistent, mechanistically coherent, and reproducible. However, speed is a surrogate outcome; the largest observational dataset raises signals of increased eclampsia, HELLP, and renal failure with nifedipine. The AUC of 0.668 quantifies the advantage as modest—statistically significant but far from the >0.80 threshold justifying categorical protocol change. Conclusion: Oral nifedipine controls hypertensive crisis significantly faster with fewer doses than labetalol, with a moderate discriminative advantage (AUC 0.668) and equivalent maternal/perinatal safety in randomized evidence. Requiring no IV access, infusion pump, or continuous cardiotocography, nifedipine should be regarded as a legitimate first-line option—and in resource-constrained settings, the preferred option.

Copyrights © 2026






Journal Info

Abbrev

ijmhsr

Publisher

Subject

Dentistry Health Professions Medicine & Pharmacology Nursing Public Health Veterinary

Description

The International Journal of Medical Science and Health Research, published by International Medical Journal Corp. Ltd. is dedicated to providing physicians with the best research and important information in the world of medical research and science and to present the information in a format that ...